Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on June 3, 2026. The report discloses a material corporate event under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of James Sapirstein as Chief Executive Officer, effective June 3, 2026. This information was disseminated via a press release furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, specific risk factors, or contingencies related to the CEO appointment. The press release referenced in the filing is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on James Sapirstein's background and the transition plan.
- Confirm the effective date of the CEO appointment and any interim leadership arrangements.
- Review subsequent filings for any impact this leadership change may have on the company's strategic direction or financial outlook.